Heart muscle is a metabolic omnivore. The normal heart derives its energy for contraction from the oxidation of longchain fatty acids. The stressed heart switches to carbohydrate substrates for greater efficiency of energy production. Here we review the evidence for glucose-insulin-potassium as an effective strategy to treat postischemic contractile dysfunction of the heart. There is a strong rationale for both glucose and insulin to restore efficient energy transfer in the metabolically depleted postischemic heart. In spite ofits long history and abundant opportunities for translational research, the field is still in its infancy. Further progress is tied to two broad areas of research: randomized, multicenter clinical trialsand systematic studies addressing cellular signaling mechanisms, including nutrient sensing of myocardial gene expression.
References
1.
1. Krebs HA, Martin A: Hans Krebs: Reminiscences and reflections. Oxford, Clarendon Press, 1981.
2.
2. Lipmann F: Metabolic generation and utilization of phosphate bond energy. Adv Enzymol1:99-165, 1941.
3.
3. Taegtmeyer H: Energy metabolism of the heart: From basic concepts to clinical applications. Curr Prob Cardiol19:57-116, 1994.
4.
4. Balaban RS: Cardiac energy metabolism homeostasis: Role of cytosolic calcium. J Mol Cell Cardiol34:1259-1271, 2002.
5.
5. Katz A: Changing strategies in the management of heart failure. J Am Coll Cardiol13:513-523, 1989.
6.
6. Atkinson DE: Cellular Energy Metabolism and Its Regulation. New York, Academic Press, 1977.
7.
7. Krebs HA: The Croonian Lecture, 1963. Gluconeogenesis. Proc R Soc London, Ser159:545-564, 1964.
8.
8. Hardie DG, Carling D: The AMP-activated protein kinasefuel gauge of the mammalian cell?Eur J Biochem246:259-273, 1997.
9.
9. Kudo N, Gillespie JG, Kung L: Characterization of 5'AMPactivated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta1301:67-75, 1996.
10.
10. Young LH, Russell RR, Yin R: Regulation of myocardial glucose uptake and transport during ischemia and energetic stress. Am J Cardiol83:25H-30H, 1999.
11.
11. Barger PM, Kelly DP: PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med10:238-245, 2000.
12.
12. Lopaschuk GD, Rebeyka IM, Allard MF: Metabolic modulation: A means to mend a broken heart. Circulation105:140-142, 200.
13.
13. Taegtmeyer H, Hems R, Krebs HA: Utilization of energy providing substrates in the isolated working rat heart. Biochem J186:701-711, 198.
14.
14. Goodwin GW, Taylor CS, Taegtmeyer H: Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem273:29530-29539, 1998.
15.
15. Goodwin GW, Taegtmeyer H: Improved energy homeostasis of the heart in the metabolic state of exercise. Am J Physiol Heart Circ Physiol279:H1490-H1501, 2000.
16.
16. Gradinak S, Coleman GM, Taegtmeyer H: Improved cardiac function with glucose-insulin-potassium after coronary bypass surgery. Ann Thorac Surg48:484-489, 1989.
17.
17. Liedtke AJ, Hacker T, Renstrom B: Anaplerotic effects of propionate on oxidations of acetate and long-chain fatty acids. Am J Physiol270:H2197-2203, 1996.
18.
18. Liu B, el Alaoui-Talibi Z, Clanachan AS: Uncoupling of contractile function from mitochondrial TCA cycle activity and MVO2 during reperfusion of ischemic hearts. Am J Physiol270:H72-H80, 1996.
19.
19. Borst P, Loos JA, Christ EJ: Uncoupling activity of long chain fatty acids. Biochim Biophys Acta62:509-517, 1962.
20.
20. Lopaschuk GD, Warmbolt RB, Barr RL: An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Experim Therap264:135-144, 1993.
21.
21. Lopaschuk GD, Wall SR, Olley PM: Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res63:1036-1043, 1988.
22.
22. Broderick T, Quinney H, Barker C: Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation87:972-981, 1993.
23.
23. Goulston A: West Indian cane sugar in the treatment of certain forms of heart disease. Brit Med J9:693-693, 1912.
24.
24. Biudingen T: Uber die Moglichkeit einer Ernahrungsbehandlung des Herzmuskels durch Einbringen von Traubenzuckerlosungen in den grogen Kreislauf. Deutsch Arch Klin Med114:534-579, 1914.
25.
25. Depre C, Vanoverschelde JLJ, Taegtmeyer H: Glucose for the heart. Circulation99:578-588, 1999.
26.
26. Haider W, Benzer H, Schutz W: Improvement of cardiac preservation by preoperative high insulin supply. J Thorac Cardiovasc Surg88:294-300, 1984.
27.
27. Hewitt R, Lolley D, Adrouney G: Protective effect of myocardial glycogen on cardiac function during anoxia. Surgery73:444-453, 1973.
28.
28. Muller JE, Mochizuki S, Koster JKJ: Insulin therapy for depressed myocardial contractility after prolonged ischemia. Am J Cardiol41:1215-1221, 1978.
29.
29. Wisneski JA, Gertz EW, Neese RA: Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest76:1819-1827, 1985.
30.
30. Taegtmeyer H, Goodwin GW, Doenst T: Substrate metabolism as a determinant for postischemic functional recovery of the heart. Am J Cardiol80:3A-1OA, 1997.
31.
31. Svedjeholm R, Huljebrant I, Hakanson E: Glutamate and high dose glucose-insulin-potassium (GIK) in the treatment of severe cardiac failure after cardiac operations. Ann Thorac Surg59:S23-S30, 1995.
32.
32. Lazar HL, Zhang X, Rivers S: Limiting ischemic myocardial damage using glucose-insulin-potassium solutions. Ann Thorac Surg60:411-416, 1995.
34. Lazar HL, Chipkin S, Philippides G: Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations. Ann Thorac Surg70:145-150, 2000.
35.
35. Sodi-Pallares D, Testelli MR, Fishleder BL: Effects of intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol9:166-181, 1962.
36.
36. Sodi-Pallares D, Bisteni A, Medrano G: The polarizing treatment of acute myocardial infarction. Dis Chest43:424-432, 1963.
37.
37. van den Berghe G, Wouters P, Weekers F: Intensive insulin therapy in critically ill patients. N Engl J Med345:1359-1367, 2001.
38.
38. Rosenfeld G: Ueber die Behandlung der Zuckerkrankheit. Berl Klin Wochenschr46:957-961, 1909.
39.
39. Russell RR, Taegtmeyer H: Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol261:H1756-H1762, 1991.
40.
40. Goodwin GW, Taegtmeyer H: Metabolic recovery of the isolated working rat heart after brief global ischemia. Am J Physiol267:H462-H470, 1994.
41.
41. Bradamante S, Marchesani A, Barenghi L: Glycogen turnover and anaplerosis in preconditioned rat hearts. Biochim Biophys Acta1502:363-379, 2000.
42.
42. Korvald C, Elvenes OP, Myrmel T: Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol278:H1345-H1351, 2000.
43.
43. Malhotra R, Brosius FC: Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes. J Biol Chem274:12567-12575, 1999.
44.
44. van Bilsen M, van der Vusse GJ, Reneman RS: Transcriptional regulation of metabolic processes: Implications for cardiac metabolism. Pflugers Arch437:2-14, 1998.
45.
45. Taegtmeyer H: Genetics of energetics: Transcriptional responses in cardiac metabolism. Ann Biomed Eng28:871-876, 2000.
46.
46. Xia Y, Wen HY, Young ME: mTOR and PKA signaling mediate the cardiac transcriptional response to glutamine. J Biol Chem (in press: 2003).
47.
47. Taegtmeyer H, Overturf ML: Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension11:416-426, 1988.
48.
48. Young ME, Guthrie P, Stepkowski S: Glucose regulation o f sarcomeric protein gene expression in the rat heart. J Molec Cell Cardiol33:A181-A181, 2001 (abstr).
49.
49. Sugden PH: Signaling pathways in cardiac myocyte hypertrophy. Ann Med33:611-622, 2001.
50.
50. Olson EN: Calcineurin signaling and muscle remodeling. Cell101:689-692, 2000.
51.
51. Moon YA, Kim KS, Cho UH: Characterization of regulatory elements on the promoter region of human ATP-citrate lyase. Exp Mol Med31:108-114, 1999.
52.
52. Vaulont S, Vasseur-Cognet M, Kahn A: Glucose regulation of gene transcription. J Biol Chem275:31555-31558, 2000.
53.
53. Proud CG: Regulation of mammalian translation factors by nutrients. Eur J Biochem269:5338-5349, 2002.
55. Shiojima I, Yefremashvili M, Luo Z: Akt signaling mediates postnatal heart growth in response to insulin and nutritional status. J Biol Chem277:37670-37677, 2002.
56.
56. Jagasia D, Whiting JM, Concato J: Effect of non-insulindependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation103:1734-1739, 2001.
57.
57. Russell RR, Mommessin JI, Taegtmeyer H: Propionyl-L-carnitine-mediated improvement in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol268:H441-H447, 1995.
58.
58. Schneider CA, Nguyefi VT, Taegtmeyer H: Feeding and fasting determine postischemic glucose utilization in isolated working rat hearts. Am J Physiol260:H542-H548, 1991.
59.
59. Schneider CA, Taegtmeyer H: Fasting in vivo delays myocardial cell damage after brief periods of ischemia in the isolated working rat heart. Circ Res68:1045-1050, 1991.
60.
60. Goodwin GW, Arteaga JA, Taegtmeyer H: Glycogen turnover in the isolated working rat heart. J Biol Chem270:9234-9240, 1995.
61.
61. Kim H, Kim D, Lee I: Human fetal heart development after mid-term: Morphometry and ultra-structural study. J Molec Cell Cardiol24:949-968, 1992.
62.
62. Jones CT, Rolph TP: Metabolism during fetal life: A functional assessment of metabolic development. Physiol Rev65:357-430, 1985.
63.
63. Neely JR, Grotyohann LW: Role of glycolytic products in damage to myocardium: Dissociation of adenosine triphosphate levels and recovery of function of reperfused canine myocardium. Circ Res55:816-824, 1984.
64.
64. Lagerstrom CF, Walker WE, Taegtmeyer H: Failure of glycogen depletion to improve left ventricular function of the rabbit heart after hypothermic ischemic arrest. Circ Res63:81-86, 1988.
65.
65. Apstein CS, Gravino FN, Haudenschild CC: Determinants of a protective effect of glucose and insulin on the ischemic myocardium. Effects on contractile function, diastolic compliance, metabolism, and ultrastructure during ischemia and reperfusion. Circ Res52:515-526, 1983.
66.
66. Chin E, Allen D: Effects of reduced muscle glycogen concentration on force, Ca2+ release and contractile protein function in intact mouse skeletal muscle. J Physiol (Lond)498:17-29, 1997.
67.
67. Smogorzewski M, Galfayan VG: MS: High glucose concentration causes a rise in [Ca2+]i of cardiac myocytes. Kidney Int.54:1206-1213, 1998.
68.
68. Taegtmeyer H: Switching metabolic genes to build a better heart. Circulation106:2043-2045, 2002. (editorial).
69.
69. Doenst T, Richwine RT, Bray MS: Insulin improves functional and metabolic recovery of reperfused working rat heart. Ann Thorac Surg67:1682-1688, 1999.
70.
70. Matsui T, Tao J, del Monte F: Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation104:330-335, 2001.
71.
71. Cook SA, Matsui T, Li L: Transcriptional effects of chronic Akt activation in the heart. J Biol Chem (pub ahead of print:2002).
72.
72. Jonassen AK, Sack MN, Mjos OD: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res89:1191-1198, 2001.
73.
73. Gottlob K, Majewski N, Kennedy S: Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev15:1406-1418, 2001.
